Compare Moderna, Inc. (MRNA) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while ProShares UltraPro Short QQQ ETF trades at $40.56. The key difference: Moderna, Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | SQQQ | |
|---|---|---|
Market Cap | $23.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $81.80 | $97.60 |
52-Week Low | $22.36 | $36.31 |
Enterprise Value | $19.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
SQQQ trades at $42.68, down 0.26% on the day, with a bullish technical signal from moving averages but neutral oscillators. As a leveraged inverse ETF, it aims to deliver -3x the daily return of the Nasdaq-100, making it a tactical tool for hedging or short-term bearish bets rather than a long-term investment. Recent news highlights its role in protecting QQQ holdings but warns of severe erosion from daily resets.
The outlook for SQQQ is highly speculative, suited only for experienced traders timing tech sector declines. Key risks include volatility decay and reliance on accurate market timing, with long-term performance showing near-total loss since inception. It offers no fundamental value like earnings or dividends, serving purely as a hedging instrument.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
